Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 253

1.

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.

Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P.

Br J Cancer. 2014 Jul 17. doi: 10.1038/bjc.2014.396. [Epub ahead of print]

PMID:
25032733
[PubMed - as supplied by publisher]
2.

ERĪ² splice variant expression in four large cohorts of human breast cancer patient tumors.

Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL.

Breast Cancer Res Treat. 2014 Jul 10. [Epub ahead of print]

PMID:
25007965
[PubMed - as supplied by publisher]
3.

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients.

Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A.

PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014.

PMID:
24968015
[PubMed - in process]
Free PMC Article
4.

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.

Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL.

BMC Cancer. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326.

PMID:
24885187
[PubMed - in process]
Free PMC Article
5.

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.

Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL.

Clin Cancer Res. 2014 Jun 15;20(12):3328-37. doi: 10.1158/1078-0432.CCR-14-0093. Epub 2014 Apr 8.

PMID:
24714776
[PubMed - in process]
6.

Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA.

Clin Cancer Res. 2014 Jun 1;20(11):3023-32. doi: 10.1158/1078-0432.CCR-14-0113. Epub 2014 Apr 3.

PMID:
24700741
[PubMed - in process]
7.

Next-gen immunohistochemistry.

Rimm DL.

Nat Methods. 2014 Apr;11(4):381-3. doi: 10.1038/nmeth.2896. No abstract available.

PMID:
24681723
[PubMed - indexed for MEDLINE]
8.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.

Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL.

Clin Cancer Res. 2014 May 15;20(10):2773-82. doi: 10.1158/1078-0432.CCR-13-2702. Epub 2014 Mar 19.

PMID:
24647569
[PubMed - in process]
9.

A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.

Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL.

Lab Invest. 2014 Apr;94(4):467-74. doi: 10.1038/labinvest.2014.7. Epub 2014 Feb 17.

PMID:
24535259
[PubMed - indexed for MEDLINE]
10.

Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer.

How J, Brown JR, Saylor S, Rimm DL.

Histochem Cell Biol. 2014 Jan 16. [Epub ahead of print]

PMID:
24429833
[PubMed - as supplied by publisher]
11.

Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method.

Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF.

PLoS One. 2013 Nov 21;8(11):e79901. doi: 10.1371/journal.pone.0079901. eCollection 2013.

PMID:
24278211
[PubMed - in process]
Free PMC Article
12.

Construction and analysis of multiparameter prognostic models for melanoma outcome.

Rothberg BE, Rimm DL.

Methods Mol Biol. 2014;1102:227-58. doi: 10.1007/978-1-62703-727-3_13. Review.

PMID:
24258982
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Programmed death ligand-1 expression in non-small cell lung cancer.

Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL.

Lab Invest. 2014 Jan;94(1):107-16. doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11.

PMID:
24217091
[PubMed - indexed for MEDLINE]
14.

Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer.

Brown JR, DiGiovanna MP, Killelea B, Lannin DR, Rimm DL.

Lab Invest. 2014 Jan;94(1):98-106. doi: 10.1038/labinvest.2013.128. Epub 2013 Nov 4.

PMID:
24189270
[PubMed - indexed for MEDLINE]
15.

A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells.

Viray H, Li K, Long TA, Vasalos P, Bridge JA, Jennings LJ, Halling KC, Hameed M, Rimm DL.

Arch Pathol Lab Med. 2013 Nov;137(11):1545-9. doi: 10.5858/arpa.2012-0561-CP.

PMID:
24168492
[PubMed - indexed for MEDLINE]
16.

A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.

Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P.

Arch Pathol Lab Med. 2014 Feb;138(2):213-9. doi: 10.5858/arpa.2012-0617-OA. Epub 2013 Oct 28.

PMID:
24164555
[PubMed - indexed for MEDLINE]
17.

Automated objective determination of percentage of malignant nuclei for mutation testing.

Viray H, Coulter M, Li K, Lane K, Madan A, Mitchell K, Schalper K, Hoyt C, Rimm DL.

Appl Immunohistochem Mol Morphol. 2014 May-Jun;22(5):363-71. doi: 10.1097/PAI.0b013e318299a1f6.

PMID:
24162261
[PubMed - in process]
18.

Gene Silencing in Skin After Deposition of Self-Delivery siRNA With a Motorized Microneedle Array Device.

Hickerson RP, Wey WC, Rimm DL, Speaker T, Suh S, Flores MA, Gonzalez-Gonzalez E, Leake D, Contag CH, Kaspar RL.

Mol Ther Nucleic Acids. 2013 Oct 22;2:e129. doi: 10.1038/mtna.2013.56.

PMID:
24150576
[PubMed]
Free PMC Article
19.

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A.

Future Oncol. 2013 Oct;9(10):1477-87. doi: 10.2217/fon.13.103.

PMID:
24106899
[PubMed - indexed for MEDLINE]
20.

Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.

Jilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM.

PLoS One. 2013 Aug 6;8(8):e69748. doi: 10.1371/journal.pone.0069748. Print 2013.

PMID:
23936348
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk